Zura Bio Q3 2026 net loss widens to $25.8 million; cash totals $187.7 million
Zura Bio reported a third-quarter 2026 net loss of $25.8 million, or $0.20 per share, up from $18.0 million, or $0.21 per share, a year earlier, as research and development and general and administrative spending rose. The company said its $187.7 million in cash and cash equivalents as of September 30, 2026 is expected to fund planned operations through at least the end of 2028, and it reaffirmed timing for topline data from two Phase 2 tibulizumab studies.
Key points
- Net loss of $25.8 million ($0.20 per share) for Q3 2026, compared with $18.0 million ($0.21 per share) in Q3 2025.
- R&D expenses rose to $19.5 million from $11.9 million; G&A expenses rose to $9.3 million from $7.6 million.
- Cash and cash equivalents were $187.7 million as of September 30, 2026, with runway expected through at least the end of 2028.
- TibuSHIELD topline data in hidradenitis suppurativa remains on track for Q4 2026, TibuSURE data in systemic sclerosis for H1 2027, and NEXUS-PMR is set to start by year-end 2026.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.